anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This is a randomized, double-blind study of ARN-75039 or placebo given as single and multiple escalating doses in normal healthy subjects. The study will be conducted in three parts: Part 1 will be a Single Ascending Dose (SAD) study enrolling approximately 40 subjects for a total duration of 6 weeks. Part 2 will be a Multiple Ascending Dose (MAD) study enrolling approximately 24 subjects for a total duration of 10 weeks, and part 3 will be a selected SAD cohort in a fasted state to evaluate the effect of food on the bioavailability of ARN-75039, enrolling approximately 8 subjects from a selected SAD cohort for a duration of 6 weeks. The dose escalation will be performed in a step-wise manner. Dose escalation stopping rules will be used to determine whether or not investigation of a higher dose level will proceed per protocol. Safety and tolerability will be assessed by periodic measurement of vital signs, physical examinations, electrocardiograms, blood laboratory analyses and occurrence of adverse events (AE). PK blood samples will be collected at pre-specified time points for noncompartmental data analysis. The PK parameters include but are not limited to: Cmax, Tmax, AUC, CL, and t½. For determination of the food effect, for selected PK parameters (e.g., Cmax, AUC0-τ, and AUC0-∞), comparisons between the fed and fasted conditions will be made.
The invention discloses a correlative gene fimL of the pseudomonsa aeruginosa biofilm forming. The invention belongs to the microorganism biological technology field. The invention is closely linked with the pathogen city research of pseudomonsa aeruginosa, the size of the gene is 1689bp, and has no reports to the gene function internationally. The loss of the twitching motility capability of IV style pilus mediation caused by the deficiency of the gene is discovered through the experiment. The IV style pilus and the twitching motility mediated by the IV style pilus play an absolutely necessary role in the early stage of the pseudomonsa aeruginosa biofilm forming. The drug fastness of the pseudomonsa aeruginosa is enhanced through the biological biofilm forming, which usually causes the intractable infection and the intractable infection in clinical practice, to be the hot problem for the clinical treatment. The correlative gene fimL of the pseudomonsa aeruginosa biofilm forming is served for the new medicine target developing antibiotic medicine, the clinical treatment, and the medicine bearing prevention.
BACKGROUND: Accumulating studies have disclosed that circular RNAs (circRNAs) are closely associated with the malignant progression of colorectal cancer (CRC). The aim of our work was to reveal the function of circ_0038718 in CRC.
METHODS: The level of genes and proteins were assessed by quantitative real-time polymerase chain reaction (qRT-PCR) and western blot. In vitro researches were executed via utilizing cell counting Kit-8 (CCK-8), EdU, flow cytometry analysis and wound-healing assay, individually. The target relationship was validated by Dual-luciferase reporter assay. In vivo assay was employed through establishing xenograft tumor model.
RESULTS: Circ_0038718 was identified to be increased in CRC tissues and cells. Circ_0038718 downregulation suppressed cell proliferation, migration and facilitated apoptosis of CRC. Mechanistically, circ_0038718 could sponge miR-761 and miR-214-3p to modulate the expression of ITGA6. The rescue experiments proved that miR-761 or miR-214-3p inhibitor attenuated the repressive impact of circ_0038718 inhibition on CRC cells progression, and overexpressed ITGA6 could weaken the inhibitory effect of miR-761 or miR-214-3p on tumor cells. Furthermore, depletion of circ_0038718 confined the tumor growth in vivo.
CONCLUSION: Circ_0038718 aggravated the progression of CRC cells via mediating ITGA6 expression through targeting miR-761 and miR-214-3p, providing a new therapeutic target for CRC patients.
Systems and methods implement a status assessment of a respiratory device with sound evaluation. In some versions, the system may include a motor operated pressure generator to generate airflow through an air circuit to a patient interface. The system may include a transducer producing a signal representing sound of the generator in the circuit. The system may include a controller, such as with a processor, for generator control. The system, such as with the controller, computes a sound representation in the frequency domain. The system applies, to the frequency domain representation, any one or more of an integer-multiple function, non-integer-multiple function, a statistical correlation function and resonant frequency function, such as of a fundamental frequency attributable to motor operation. The system may derive a noise vector with data from the function(s). The system may classify the vector to obtain a status indicator of the generator and generate indicator related output.
PROBLEM TO BE SOLVED: To solve a discoloration problem without using a stabilizer or the like by filling a spray liquid having a specified pH and an inert gas in a compressed condition, in a spray container using the spray liquid containing ascorbic acid useful for a lotion protecting hair, skin, etc., from ultraviolet ray. SOLUTION: A liquid containing at least one kind selected from a group constituted of ascorbic acid and its salts is used for a spray liquid filling a jett pipe type spraying container. In this time, the spray liquid is adjusted to be about 3.4-8.0 in pH. This spray liquid is filled in a compressed condition of an inert gas to constitute the spray container in order to prevent discoloration or the like of the liquid contents. The total content of at least one kind of substance selected from a group constituted of ascorbic acid and its salts is not especially limitted but it is used in a range of 0.01-30 wt.%. One or more of water and water-soluble alcohol are used as a solvent.
Treatment Plan After patient screening, patients will receive treatment with trastuzumab injection plus either pyrotinib maleate tablets or neratinib maleate tablets, with each cycle lasting 14 days until disease progression. Trastuzumab Injection: Intravenous infusion, initial loading dose of 2 mg/kg, administered via intravenous infusion over 30-90 minutes (usually recommended around 60 minutes), administered on day 1 of each cycle, with each cycle lasting 14 days. Pyrotinib Maleate Tablets: 400 mg, taken orally once daily, within 30 minutes after a meal, at the same time every day. Taken continuously, with each cycle lasting 14 days. If a patient misses a dose of pyrotinib, it should not be made up for, and the next dose should be taken as scheduled. Neratinib Maleate Tablets: 240 mg, taken orally once daily with a meal, at the same time every day. The neratinib tablet should be swallowed whole (it should not be chewed, crushed, or split before swallowing). Taken continuously, with each cycle lasting 14 days. If a patient misses a dose of neratinib, it should not be made up for, and the next dose should be taken as scheduled. Note: The choice between pyrotinib maleate tablets or neratinib maleate tablets for treatment should be based on the patient's previous treatment history as decided by the investigator. Treatment medication should be continued until disease progression or the occurrence of intolerable toxic reactions.

Study Steps 1) Screening Period (Visit 1: -14 to -1 days, approximately 2 weeks): Subjects will sign an informed consent form during Visit 1 and undergo a series of examinations (see Table 1. Treatment Flowchart). Based on the examination results and inclusion/exclusion criteria, the investigator will determine if the subject meets the inclusion criteria and does not meet the exclusion criteria. 2) Treatment Period (Visit 2 to disease progression, 1 visit every 2 cycles): Subjects will receive treatment with trastuzumab injection plus pyrotinib maleate tablets plus capecitabine tablets on the experimental Day 0, with each cycle lasting 21 days, until disease progression. During this period, a series of examinations will be conducted every 2 cycles (see flowchart for visits 2 to N). The investigator will evaluate the effectiveness and safety of the treatment based on the subject's examination results. 3) Survival Follow-up Period (1 follow-up every 3 months after withdrawal from the study): After patients withdraw due to disease progression or other endpoint events, a telephone follow-up will be conducted every 3 months until the patient's death or loss to follow-up. Detailed records of disease progression, related treatments, and survival information should be documented.
The invention discloses a Chinese medicinal composition for treating diabetes and a preparation method of the Chinese medicinal composition. The Chinese medicinal composition comprises the following raw materials in parts by weight: 20 of Pueraria root, 30 parts of Fiveleaf gynostemma, 50 parts of pumpkin, 50 parts of microcrystalline cellulose and 0.5 part of magnesium stearate. The Chinese medicinal composition in a capsule form is formulated based on the health protection theories in traditional Chinese medicine and can achieve the effect of treating diabetes. The Chinese medicinal composition comprises Pueraria root, Fiveleaf gynostemma and pumpkin, which are major materials and are made by scientific and reasonable production processes. The product has definite functions and controllable quality and is safe for taking. The preparation method is simple and is implemented by using the conventional equipment.
The use of lupulones (I) is claimed for the production of compositions for inhibiting the formation of abnormal crypt sites, formation of polyps and cancerization of polyps in the mucosa of the colon of a mammal (specifically a human). Independent claims are included for functional foods and food supplements containing (I). ACTIVITY : Cytostatic. In tests in rats injected intraperitoneally with azoxymethane as colorectal carcinogenesis inducer, administration of lupolones at a dose of 5 mg/kg per day (in the form of a lupulone-containing extract of whirlpool turbidity formed in beer production, contained in a drink) for 6 weeks reduced the number of precancerous lesions in the mucosa of the colon by ca. 50%. MECHANISM OF ACTION : Programmed cell death inducer; Cell cycle modulator; Caspase activator; DNA fragmentation inducer.
A medical system comprising a patch device and a computer. The patch device is in communication with the computer. The patch device is configured for generating measurement data or providing a therapy. The patch device comprises electronic circuitry, a battery, an antenna system, one or more sensors, an IMU (inertial measurement unit), and a flexible enclosure. The antenna system can comprise a dual antenna formed on a dielectric substrate with a first antenna on a first side of the dielectric substrate and a second antenna on a second side of the dielectric substrate. The one or more sensors can comprise devices configured to provide measurement data or a therapy. The IMU is configured to measure position, movement, and trajectory of the patch device. The electronic circuitry is configured to harvest energy from one or more radio frequency signals received by the antenna system to recharge the battery.
FIELD: biotechnology. SUBSTANCE: invention relates to methods of molecules incorporation in cells. Device has the source of gas, reservoir for material to be incorporated, agent for feeding material, chamber for material incorporation in cells. Material is fixed on carrier particles in the gaseous flow under increased pressure and contacted with cells to be treated. EFFECT: improved method of incorporation. 10 cl, 12 dwg , 1 tbl
Evoked potentials will be recorded from brain area M1 (motor cortex) in combination with a speech motor learning procedure known as adaptation to altered auditory feedback. Retention of learning will be tested 24h later along with additional evoked potential recordings.
INTRODUCTION: In the treatment of chronic prosthetic joint infection (PJI) of the hip, two-stage exchange arthroplasty is commonly employed. Various spacer designs, including Hemi-Spacers and Articulating Spacers, are utilized during this process. However, these spacers are associated with a high rate of mechanical complications and pose a risk of progressive bone loss. This study aims to compare these two types of spacers in terms of mechanical complications, center of rotation (COR) restoration, and preservation of acetabular bone stock.
MATERIALS AND METHODS: From 2019 to 2022, patients who underwent two-stage exchange arthroplasty for hip PJI across three hospitals were retrospectively reviewed. Data including demographic, clinical, and microbiological information were collected. Radiographic imaging was analyzed to measure acetabular bone erosion, COR, and periacetabular bone resected. Additionally, the average surgical time in the first and second stages, mechanical complications, and the mean duration of the inter-stage period were recorded.
RESULTS: Forty patients were divided into two groups: Group A (Articulating Spacer, n = 23) received a preformed femur spacer with acetabular cement augmentation, while Group B (Hemi-Spacer, n = 17) received a preformed femur spacer alone. Acetabular cement augmentation slightly prolonged the first stage but facilitated a faster second stage during subsequent reimplantation. Spacer dislocation rates were 8.7% in Group A and 17.6% in Group B during the interstage period. Radiographic analysis revealed a statistically significant greater degree of acetabular erosion in Group B. A significant difference in Vertical-COR differential was observed, with a more proximalized revision cup compared to the primary cup in Group B, and Horizontal-COR values closer to the native hip in Group A.
CONCLUSIONS: Dynamic spacers with acetabular cement augmentation help preserve peri-acetabular bone stock and prevent progression of acetabular bone erosion during the inter-stage period. Additionally, these spacers reduce the dislocation rates, making reimplantation easier and leading to better restoration of hip biomechanics during the second procedure.
Menopausal transition has been related to stress urinary incontinence. The transition from the reproductive to the non-reproductive period is induced by a decrease in sex hormone production in the ovaries. Climacteric-stage oestrogen deficiency produces genital and urinary tract atrophy, which may be related to symptoms such as urinary frequency, urinary urgency, nocturia incontinence, and recurrent urinary tract infection. Urinary incontinence seems to appear due to a combination of factors such as pelvic floor weakness and tearing, denervation and fascial tears as well as both loss of motor units and altered activation patterns. However, physiotherapy can treat weakness and altered motor control in order to compensate for other factors. In fact, physiotherapy is considered the treatment of first choice.

Besides evidence defending physiotherapy as first line conservative therapy in incontinence due to influence of strength and motor control in this pathology and its prevalence in perimenopause women, little is known about its effects in this population. Hence, the aim of this study is to evaluate the short and long term effectiveness of a tailored assessment and educational intervention on motor control of the pelvic floor muscle in menopausal and peri-menopausal women.
Treatment with pimozide tablets, USP exposes the patient to serious risks. A decision to use pimozide tablets, USP chronically in Tourette’s Disorder is one that deserves full consideration by the patient (or patient’s family) as well as by the treating physician. Because the goal of treatment is symptomatic improvement, the patient’s view of the need for treatment and assessment of response are critical in evaluating the impact of therapy and weighing its benefits against the risks. Since the physician is the primary source of information about the use of a drug in any disease, it is recommended that the following information be discussed with patients and/or their families.

Pimozide tablets, are intended only for use in patients with Tourette’s Disorder whose symptoms are severe and who cannot tolerate, or who do not respond to HALDOL® (haloperidol).

Given the likelihood that a proportion of patients exposed chronically to antipsychotics will develop tardive dyskinesia, it is advised that all patients in whom chronic use is contemplated be given, if possible, full information about this risk. The decision to inform patients and/or their guardians must obviously take into account the clinical circumstances and the competency of the patient to understand the information provided.

There is limited information available on the use of pimozide tablets, USP in children under 12 years of age.

The information available on pimozide tablets, USP from foreign marketing experience and from U.S. clinical trials indicates that pimozide tablets, have a side effect profile similar to that of other antipsychotic drugs. Patients should be informed that all types of side effects associated with the use of antipsychotics may be associated with the use of pimozide tablets.

In addition, sudden, unexpected deaths have occurred in patients taking high doses of pimozide tablets, USP for conditions other than Tourette’s Disorder. These deaths may have been the result of an effect of pimozide upon the heart. Therefore, patients should be instructed not to exceed the prescribed dose of pimozide tablets, USP and they should realize the need for the initial ECG and for follow-up ECGs during treatment.

Also, pimozide, at a dose about 15 times that given humans, caused an increase in the number of benign tumors of the pituitary gland in female mice. It is not possible to say how important this is. Similar tumors were not seen in rats given pimozide, nor at lower doses in mice, which is reassuring. However, any such finding must be considered to suggest a possible risk of long term use of the drug.  
  
Because substances in grapefruit juice may inhibit the metabolism of pimozide by CYP 3A4, patients should be advised to avoid grapefruit juice.
Hepatosplenic schistosomiasis is a complex clinical condition caused by the complications of chronic infection with Schistosoma species that cause intestinal schistosomiasis. Hepatosplenic schistosomiasis derives from the fibrotic reaction stimulated around parasite eggs that are transported by the mesenteric circulation to the liver, causing periportal fibrosis. Portal hypertension and variceal gastrointestinal bleeding are major complications of hepatosplenic schistosomiasis. The clinical management of hepatosplenic schistosomiasis is not standardised and a parameter that could guide clinical decision making has not yet been identified. Transjugular intrahepatic portosystemic shunt (TIPS) appears promising for use in hepatosplenic schistosomiasis but is still reported in very few patients. In this Grand Round, we report one patient with hepatosplenic schistosomiasis treated with TIPS, which resulted in regression of oesophageal varices but had to be followed by splenectomy due to persisting severe splenomegaly and thrombocytopenia. We summarise the main challenges in the clinical management of this patient with hepatosplenic schistosomiasis, highlight results of a scoping review of the literature, and evaluate the use of of TIPS in patients with early hepatosplenic schistosomiasis, to improve the prognosis.
PURPOSE:A safe antitumor agent containing a lactose ester of a fatty acid obtained by condensing lactose with a specific fatty acid as an active constituent with side effects. CONSTITUTION:An antitumor agent containing a lactose ester of a fatty acid obtained by condensing lactose with an 8-22C saturated or unsaturated fatty acid, e.g. stearic, caprylic, palmitoleic or oleic acid, as an active constituent. The active constituent is dissolved or suspended in physilological saline solution and administered orally or intravenously. The dose thereof is 10-5mg/kg/day for the oral administration, and 1-5mg/kg/day for the intravenous administration. The lactose ester of the fatty acid may be an emulsifiable substance, having the number of introduced fatty acid of about 1-3 (molar ratio) into the lactose, soluble in cold-warm water, and capable of giving an aqueous solution having a very high ability to reduce the surface tension thereof.
PCT No. PCT/US95/02645 Sec. 371 Date Jan. 30, 1998 Sec. 102(e) Date Jan. 30, 1998 PCT Filed Mar. 1, 1995 PCT Pub. No. WO96/27009 PCT Pub. Date Sep. 6, 1996A Human amine transporter polypeptide and DNA (RNA) encoding such polypeptide and a procedure for producing such polypeptide by recombinant techniques is disclosed. Also provided are methods for detecting agonists and antagonists to such polypeptide and the use of agonists and antagonists for treating diseases related to the under-expression and over-expression of the Human amine transporter of the present invention. Also disclosed are methods for detecting mutations in the nucleic acid sequence encoding the polypeptide and for detecting altered levels of the soluble form of the polypeptide.
Merci Retriever is the predicate product that received FDA clearance in 2004. Merci Retriever a first generation mechanical thrombectomy device intended to remove clot and restore blood flow in a neurovascular vessel in the setting of acute ischemic stroke.
PURPOSE: A pharmaceutical composition for anticancer containing pyrogallol is provided to suppress growth of lung cancer cells by inducing apoptosis of the lung cancers. CONSTITUTION: A pharmaceutical composition for anticancer contains pyrogallol as an active ingredient. Cancer is lung cancer or gastric cancer including adenocarcinoma. The composition downregualtes cyclin D, CDK1, CDK2, CDK4 and CDK6 expression and upregulates cyclin A and B expression. The pyrogallo increases intracellular ROS, reduce glutathione, and induces apoptosis of gastric cancer cells. The pharmaceutical composition is administered to oral, muscle, or vein.
Viral proteins derived from an enterically transmitted non-A/non-B viral hepatitis agent (HEV) are disclosed. In one embodiment, the protein is immunologically reactive with antibodies present in individuals infected with the viral hepatitis agent. This protein is useful in a diagnostic method for detecting infection by the enterically transmitted agent. Specific epitopes have been identified that are reactive with sera of individual infected with different strains of HEV. Also disclosed are DNA probes derived from a cloned sequence of the viral agent. These probes are useful for identifying and sequencing the entire viral agent and for assaying the presence of the viral agent in an infected sample, by using probe-specific amplification of virus-derived DNA fragments.
The majority of patients with multiple sclerosis (MS) suffer from some form of anorectal dysfunction, and these difficulties with bowel function are often ranked as negatively impactful on quality of life as impaired mobility. Despite the significant clinical burden of these symptoms, there remains a paucity of published literature supporting specific therapeutic options to manage anorectal dysfunction in this clinical population. Most bowel regimens rely on either oral laxatives (i.e. PEG-3350) or anti-diarrheal agents (i.e. loperamide). In their study, the investigators propose to establish the efficacy of a bowel regimen that combines both oral agents (as needed; standard care) with scheduled, every other day dosing of a placebo or stimulant laxative rectal suppository -- bisacodyl 10 mg.

Bisacodyl is a stimulant laxative medication that is available over-the-counter. It works by activating nerves in the rectum to elicit rectal contractions which ultimately leading to defecation.